Okanvision Bio-B (01477) is now up more than 7%. As of press release, it is up 7.57% to HK$5.97, with a turnover of HK$10.8087 million.
The Zhitong Finance App learned that Okanvision Bio-B (01477) is now up more than 7%. As of press release, it has risen 7.57% to HK$5.97, with a turnover of HK$10.8087 million.
According to the news, on March 11, the official website of the State Drug Administration revealed that Sinqi Pharmaceutical's atropine sulphate eye drops were approved for marketing on March 5, 2024. Guojin Securities released a research report saying that atropine sulphate eye drops have good safety and usage compliance. At this stage, there is a high incidence of myopia among children and adolescents in China, and demand for myopia prevention and control is strong. Atropine sulphate eye drops are expected to be rapidly dosed with strong product strength.
Oconvision Biotech announced in July last year that the OT-101-S domestic phase III clinical trial application was accepted by the Drug Evaluation Center (CDE) of the China Drug Administration. According to reports, OT-101-S (0.01% and 0.05% atropine sulfate eye drops) is a low concentration (0.01% and 0.05%) atropine sulfate eye drops developed by the group to slow or slow the progression of myopia in children.